Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy.

Authors:
van der Wilk BJ; Eyck BM; Noordman BJ; Kranenburg LW; Oppe M and 4 more

Journal:
Ann Surg Oncol

Publication Year: 2023

DOI:
10.1245/s10434-023-14028-8

PMCID:
PMC10625935

PMID:
37587357

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ann Surg Oncol

Abbreviation: Ann Surg Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: General Surgery

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients.
Mantziari S; Farinha HT; Messier M and 6 more (2024) - Transparency Score: 3/6
Paradigm Shifting Research: Key Studies in Urologic Oncology.
Dason S; Lee CT. (2024) - Transparency Score: 2/6
Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equiva…
Roshan A; Shah B; Anderson KD and 6 more (2024) - Transparency Score: 4/6
2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Mal…
Hübner M; van Der Speeten K; Govaerts K and 4 more (2023) - Transparency Score: 2/6
Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early…
Cabrera S; Gómez-Hidalgo NR; García-Pineda V and 29 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors declare that they have no conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025